Breaking News Instant updates and real-time market news.

EPZM

Epizyme

06:31
11/28/16
11/28
06:31
11/28/16
06:31

Epizyme announces Fast Track designation for Tazemetostat in DLBCL

Epizyme announced advancements in the company's clinical programs evaluating tazemetostat, its first-in-class EZH2 inhibitor. The U.S. FDA has granted tazemetostat Fast Track designation in patients with diffuse large B-cell lymphoma with EZH2 activating mutations. Additionally, Epizyme is focusing its Phase 2 registration-enabling study in adult patients with genetically-defined solid tumors on those cancers marked by loss of INI1, and has expanded enrollment in the epithelioid sarcoma cohort of the study based on encouraging early activity in this patient population

  • 03

    Dec

EPZM Epizyme

04/05/16
04/05/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Citi by analyst Robyn Karnauskas, who said long-term platform valuation could come in 2017. 2. AT&T (T) initiated with an Outperform at Macquarie. 3. General Dynamics (GD) initiated with a Buy at Guggenheim. 4. Grainger (GWW) initiated with an Outperform at BMO Capital. 5. McDonald's (MCD) initiated with a Hold at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/20/16
RBCM
06/20/16
NO CHANGE
RBCM
Epizyme data could improve over time, says RBC Capital
After the overall response rate of refractory non-Hodgkin lymphoma patients taking Epizyme's Tazemetostat came in at 28%, down from 56% and 60% in prior trials, RBC Capital says that the data could improve over time. Specifically, the firm thinks that some of the patients whose tumors shrunk may become responsive over the longer term. Additionally, RBC Capital reports that there was a 100% overall response rate in the FL EZH2 mutant arm of the trial. The firm keeps an Outperform rating on the shares.
08/09/16
LEER
08/09/16
NO CHANGE
Target $39
LEER
Outperform
Epizyme weakness unwarranted, says Leerink
Leerink analyst Seamus Fernandez says Epizyme announced during its Q2 earnings call that it now plans to report results from its two ongoing Phase 2 trials of tazemetostat in the first half of 2017, rather than at medical conferences in late 2016 as previously anticipated. The analyst believes the delay may allow for data to mature and says the weakness in the stock is unwarranted. Fernandez reiterates an Outperform rating and $39 price target on the shares.
09/21/16
09/21/16
NO CHANGE

Epizyme collaborates with Foundation Medicine for tazemetostat Phase 2 trial
Epizyme (EPZM) has entered into a collaboration agreement with Foundation Medicine FMI) to support patient identification and enrollment for Epizyme's ongoing Phase 2 clinical trial of tazemetostat in patients with non-Hodgkin lymphoma. Foundation Medicine's SmartTrials Precision Enrollment Program and FoundationOne Heme panel will assist in identifying a population of individuals with NHL who harbor EZH2 mutations and constitute specific cohorts in the Epizyme trial. Tazemetostat is Epizyme's oral, first-in-class EZH2 inhibitor being investigated in multiple ongoing clinical trials. Early clinical data suggest tazemetostat has encouraging clinical activity and a favorable safety profile in patients with relapsed and refractory NHL.

TODAY'S FREE FLY STORIES

SQ

Square

$15.14

0.51 (3.49%)

15:20
02/22/17
02/22
15:20
02/22/17
15:20
Options
Square options imply 11.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TIME

Time Inc.

$19.10

-0.3 (-1.55%)

, MDP

Meredith

15:19
02/22/17
02/22
15:19
02/22/17
15:19
Periodicals
Time Inc only entertaining bids for entire company, NY Post says »

A breakup of Time Inc…

TIME

Time Inc.

$19.10

-0.3 (-1.55%)

MDP

Meredith

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

$NSD

NASDAQ Market Internals

15:17
02/22/17
02/22
15:17
02/22/17
15:17
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:17
02/22/17
02/22
15:17
02/22/17
15:17
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPB

Campbell Soup

$59.16

0.21 (0.36%)

, KMB

Kimberly-Clark

$135.98

1.34 (1.00%)

15:16
02/22/17
02/22
15:16
02/22/17
15:16
Periodicals
Campbell Soup, Kimberly-Clark rumored as takeover targets, Kass says »

Doug Kass of TheStreet…

CPB

Campbell Soup

$59.16

0.21 (0.36%)

KMB

Kimberly-Clark

$135.98

1.34 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 27

    Feb

  • 19

    Mar

AOLS

Aeolus Pharmaceuticals

$0.19

-0.006 (-3.06%)

15:14
02/22/17
02/22
15:14
02/22/17
15:14
Hot Stocks
Aeolus Pharmaceuticals initiates Phase 1 study of AEOL 10150 »

Aeolus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:10
02/22/17
02/22
15:10
02/22/17
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SA

Seabridge Gold

$11.35

-0.2 (-1.73%)

15:07
02/22/17
02/22
15:07
02/22/17
15:07
Hot Stocks
Seabridge Gold completes sale of Castle-Blackrock claims to Columbus Gold »

Seabridge Gold reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCN

Ocwen

$5.33

-0.21 (-3.79%)

15:05
02/22/17
02/22
15:05
02/22/17
15:05
Options
Ocwen options imply 15.4% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AJRD

Aerojet Rocketdyne

$19.17

-0.16 (-0.83%)

, LLL

L-3 Communications

$168.49

-0.31 (-0.18%)

15:02
02/22/17
02/22
15:02
02/22/17
15:02
Hot Stocks
Aerojet Rocketdyne to acquire Coleman Aerospace for $15M in cash »

Aerojet Rocketdyne (AJRD)…

AJRD

Aerojet Rocketdyne

$19.17

-0.16 (-0.83%)

LLL

L-3 Communications

$168.49

-0.31 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DO

Diamond Offshore

$16.84

-0.52 (-3.00%)

15:01
02/22/17
02/22
15:01
02/22/17
15:01
Options
Diamond Offshore draws opening call writing »

Diamond Offshore draws…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCRA

Vocera

$19.91

-0.035 (-0.18%)

14:59
02/22/17
02/22
14:59
02/22/17
14:59
Conference/Events
Vocera management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 21

    Mar

PCTY

Paylocity

$36.86

0.59 (1.63%)

14:55
02/22/17
02/22
14:55
02/22/17
14:55
Conference/Events
Paylocity management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

SCMP

Sucampo

$12.60

0.8 (6.78%)

, NILE

Blue Nile

14:55
02/22/17
02/22
14:55
02/22/17
14:55
Hot Stocks
Sucampo to replace Blue Nile in the S&P 600 as of February 23 open »

Sucampo Pharmaceuticals…

SCMP

Sucampo

$12.60

0.8 (6.78%)

NILE

Blue Nile

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

BPT

BP Prudhoe Bay

$29.68

-0.8716 (-2.85%)

14:53
02/22/17
02/22
14:53
02/22/17
14:53
Periodicals
BP Prudhoe Bay mentioned cautiously in a Seeking Alpha Pro article 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$277.39

5.16 (1.90%)

, GM

General Motors

$37.83

0.02 (0.05%)

14:52
02/22/17
02/22
14:52
02/22/17
14:52
Earnings
On The Fly: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

TSLA

Tesla

$277.39

5.16 (1.90%)

GM

General Motors

$37.83

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

FIT

Fitbit

$5.81

-0.23 (-3.81%)

14:51
02/22/17
02/22
14:51
02/22/17
14:51
Options
Healthy volume in FitBit weekly options ahead of earnings later today »

Healthy volume in FitBit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

TSLA

Tesla

$277.39

5.16 (1.90%)

14:50
02/22/17
02/22
14:50
02/22/17
14:50
Options
Tesla options imply 9.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

PM

Philip Morris

$104.33

-0.23 (-0.22%)

14:49
02/22/17
02/22
14:49
02/22/17
14:49
Earnings
Philip Morris raises FY17 EPS view to $4.80-$4.95 from $4.70-$4.85 »

Consensus $4.80. PMI is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBPB

Potbelly

14:46
02/22/17
02/22
14:46
02/22/17
14:46
Conference/Events
Potbelly management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 08

    Mar

APA

Apache

$55.25

-0.64 (-1.15%)

, HRL

Hormel Foods

$37.21

-0.39 (-1.04%)

14:44
02/22/17
02/22
14:44
02/22/17
14:44
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

APA

Apache

$55.25

-0.64 (-1.15%)

HRL

Hormel Foods

$37.21

-0.39 (-1.04%)

KSS

Kohl's

$41.28

-0.5 (-1.20%)

PF

Pinnacle Foods

$54.75

-0.49 (-0.89%)

CHK

Chesapeake

$5.97

-0.11 (-1.81%)

CNK

Cinemark

$43.25

0.37 (0.86%)

AMCX

AMC Networks

$57.69

1.86 (3.33%)

W

Wayfair

$41.08

0.82 (2.04%)

SFM

Sprouts Farmers Markets

$19.32

0.2 (1.05%)

TREE

LendingTree

$113.60

0.65 (0.58%)

TXMD

TherapeuticsMD

$5.56

-0.03 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 28

    Mar

  • 07

    May

  • 11

    May

TSLA

Tesla

$277.39

5.16 (1.90%)

, HPQ

HP Inc.

$16.15

0.02 (0.12%)

14:44
02/22/17
02/22
14:44
02/22/17
14:44
Earnings
Notable companies reporting after market close »

Notable companies…

TSLA

Tesla

$277.39

5.16 (1.90%)

HPQ

HP Inc.

$16.15

0.02 (0.12%)

CTRP

Ctrip.com

$47.06

1.43 (3.13%)

ETE

Energy Transfer Equity

$18.90

-0.15 (-0.79%)

LB

Labarge

RRC

Range Resources

$30.27

-0.15 (-0.49%)

SQ

Square

$15.10

0.47 (3.21%)

RIG

Transocean

$13.23

-0.245 (-1.82%)

SLCA

U.S. Silica

$59.37

1.27 (2.19%)

JACK

Jack in the Box

$107.37

-0.09 (-0.08%)

CAKE

Cheesecake Factory

$60.67

-1.16 (-1.88%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

FIT

Fitbit

$5.81

-0.23 (-3.81%)

ELGX

Endologix

$6.49

-0.27 (-3.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 08

    Mar

  • 21

    Mar

  • 23

    Mar

  • 27

    Mar

  • 17

    Apr

I

Intelsat

$4.48

-0.19 (-4.07%)

14:41
02/22/17
02/22
14:41
02/22/17
14:41
Options
Ambitious call buying in Intelsat as shares drop off 52-week highs »

Ambitious call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

TPIV

TapImmune

$4.30

-0.1 (-2.27%)

14:38
02/22/17
02/22
14:38
02/22/17
14:38
Periodicals
TapImmune cancer vaccine efforts highlighted in Fox News affliate report »

Fox News 13 of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$93.78

-0.74 (-0.78%)

14:36
02/22/17
02/22
14:36
02/22/17
14:36
Options
LyondellBasell put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.